Ozempic's Impact On Brain Chemistry May Influence Depression Risk: Study
Researchers have discovered a possible connection between popular weight loss medications, such as Ozempic and Wegovy, and brain changes that may lead to depression. These medications, known as GLP-1 drugs, mimic a natural hormone that regulates blood sugar and appetite. However, studies suggest they may also affect parts of the brain related to dopamine, a chemical linked to feelings of pleasure and reward.
According to the research that was published in the journal Current Neuropharmacology, GLP-1 drugs may disrupt dopamine levels, potentially leading to depression and suicidal thoughts in individuals with low dopamine function. While these medications show promise in treating obesity and diabetes, further investigation is needed to understand their potential impact on mental health.
As per a news release, the study, led by researchers across the United States, Brazil, Iran, and Israel, demonstrates that while GLP1 agonists benefit individuals with hyperdopaminergia (excess dopamine activity), they may have harmful effects on individuals with hypodopaminergia (low dopamine function). The authors found genetic associations between GLP1 receptor agonists and genes such as DRD3, BDNF, and CREB1, which are implicated in mood regulation and reward pathways. Their findings suggest that chronic use of these drugs could dysregulate dopamine signalling, potentially leading to depressive symptoms, mood disturbances, and SI.
Cautionary Voices from Experts
While the idea of GLP-1 agonism induction of depression and SI is controversial with both negative and positive reporting, based on the evidence presented in this article by Alireza Sharafshah, a PhD candidate from the Cellular and Molecular Research Centre, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran, the authors caution against promoting chronic stimulation via GLP-1 agonists.
"This study should not be ignored, despite the hype surrounding the positive clinical outcomes of GLP-1 receptor agonists," said senior author Dr Kenneth Blum, research professor at Western University Health Sciences and Ariel University. "We urge the clinical prescribing community to proceed with caution to avoid another tragic wave of 'people dying to lose weight'."
Dr Mark S Gold, an addiction psychiatry pioneer and co-author, emphasised, "The paper provides critical evidence for re-evaluating the widespread use of GLP1 receptor agonists. The FDA and other regulatory agencies should carefully consider our findings when it comes to labelling and monitoring these drugs."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
6 hours ago
- The Print
Study of young exoplanets reveals new insights into their formation
'When we looked at the smaller, farther-out companion (planet), known as YSES 1-c, we found the tell-tale signature of silicate clouds in the mid-infrared (using the James Webb Space Telescope),' co-author Evert Nasedkin, a postdoctoral fellow in Trinity College Dublin's school of physics, Ireland, said. In one of the planets, known to orbit a sun-like star 'YSES-1', researchers detected clouds containing sand-like particles — or silicate clouds — the strongest one seen on an exoplanet yet, they said. New Delhi, Jun 11 (PTI) Astrophysicists have gained new insights into how planets outside the solar system, or 'exoplanets', form by studying two 'young' giant planets, 'still hot from their formation', a new study says. The author added this is the 'strongest silicate absorption feature observed in an exoplanet yet' and related to its youth. 'We believe this is linked to the relative youth of the planets: younger planets are slightly larger in radius, and this extended atmosphere may allow the cloud to absorb more of the light emitted by the planet,' Nasedkin said. In the study published in the journal Nature, the authors wrote, 'With two exoplanets around a solar-type star, the YSES-1 system is an ideal laboratory for studying this early phase of exoplanet evolution.' The findings help understand how the 'YSES-1' solar system formed, offering further insight into the origins of our solar system, the researchers said. 'Directly imaged exoplanets — planets outside our own Solar System — are the only exoplanets that we can truly take photos of,' Nasedkin said. 'These exoplanets are typically still young enough that they are still hot from their formation, and it is this warmth, seen in the thermal infrared, that we as astronomers observe,' the author said. Studying the other planet 'YSES-1b', the team found that the entire planetary system is young, at 16.7 million years old, yet is too old to find signs of the planet-forming disk — a mixture of gas and dust rotating a star and from which planets can form. But around YSES-1b, the team observed a disk around the planet itself, thought to feed material onto the planet and serve as the birthplace of moons — similar to those seen around Jupiter, they said. Only three other such disks have been identified to date, both around objects significantly younger than YSES-1b, raising new questions as to how this disk could be so long-lived, the researchers said. PTI KRS KRS MPL MPL This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Time of India
12 hours ago
- Time of India
JD Vance's wild take on weight loss drug Ozempic sparks criticism
Politicians usually avoid cracking jokes about eating habits—especially when it comes to weight loss drugs. But not JD Vance. The Vice President of the United States stunned listeners with a strange and awkward take on the popular diabetes and weight loss drug Ozempic, casually tossing in a cannibalism reference that many are calling "gross" and "tone-deaf. Tired of too many ads? go ad free now " On a recent appearance on comedian Theo Von's podcast, Vance launched into an unscripted riff about a medical commercial he'd seen. 'I only saw it briefly,' he said, 'but I could have sworn that two of the medications in this med pack were—Ivermectin and Ozempic. And I'm like thinking to myself, what is the situation where you need emergency Ozempic?' Then came the part that really raised eyebrows. With a laugh, Vance added, 'I thought like, you know, if you have a Donner Party situation... and it's like alright, we gotta suppress our appetites.' Wait—what? What was the Donner Party? Credit: X/@pitsenberger To decode Vance's joke, you'd have to go back to 1846, when a group of American pioneers known as the Donner Party became stranded in the Sierra Nevada mountains while traveling to California. With winter closing in and food supplies exhausted, some members of the group reportedly resorted to cannibalism to survive. It's a dark, tragic chapter in American history—and probably not the best setup for a punchline about a modern weight-loss drug. Social media reactions Social media lit up in the hours after the podcast aired, with critics slamming Vance for making light of both the desperation of the Donner Party and the medical struggles of people using Ozempic. Many pointed out that the drug is not just used by people who want to lose weight, but is also used by diabetes patients. One user commented, 'Ozempic was designed for patients with diabetes, and people with the disease also use it, J Dunce. Diabetes can be caused by other conditions, like pancreatitis and pregnancy. ' Another commented, 'What kinda of #weirdo uses "Donner Party" as the metric to evaluate bulimic therapy???' A third said, 'Why is he talking like he is expert on something he doesn't know about? Ozempic is a diabetic drug. Tired of too many ads? go ad free now It helps to regulate sugar in diabetics.' What is Ozempic? Ozempic is a prescription medication primarily used to help manage type 2 diabetes. It works by mimicking a natural hormone that regulates blood sugar levels and slows digestion, which can help people feel fuller for longer. While not originally developed as a weight loss drug, one of its side effects is appetite suppression—leading to noticeable weight loss in many patients. In recent years, Ozempic has entered the public conversation beyond diabetes care, with growing demand among people seeking medical help for obesity.
Time of India
12 hours ago
- Time of India
McDonald's downgraded amid Ozempic craze - investors worry fast food losing charm, stock under pressure
McDonald's stock was downgraded by analysts following concerns that weight-loss drugs like Ozempic could curb fast-food demand. Analysts suggested that these drugs, which reduce appetite, might lead to a significant drop in customer visits, potentially costing the company millions in revenue. Tired of too many ads? Remove Ads Equity Firm Downgrades McDonald's Stock How GLP-1 Medications Could Disrupt Fast Food Demand McDonald's Potential Revenue Losses and Customer Visit Declines Tired of too many ads? Remove Ads Inflation Adds Fuel to McDonald's Challenges Not Many Americans Are Using These Drugs Yet FAQs McDonald's faced a rough day on Wall Street Tuesday as shares dipped 1.7%, shaken by growing concerns that popular weight-loss drugs like Ozempic could seriously cut into the fast food giant's business, as per a analysis firm Redburn Atlantic lowered its rating on McDonald's stock by two notches from 'buy' to 'sell,' warning that the widespread use of GLP-1 drugs, which curb appetite and help regulate blood sugar, may change how Americans eat, potentially leading to a drop in millions of visits to McDonald's every year, as per CBS Redburn analysis described GLP-1 drugs like Ozempic and Wegovy as "demand disruptors" for restaurants like McDonald's , as they reduce consumers' appetites and limit the number of calories they consume each day, reported CBS News. Analysts wrote that, "These features of the drugs could have serious implications for the restaurant industry," according to the READ: YouTube loosens content rules, says freedom of expression can outweigh harm—controversial videos may return Analysts Chris Luyckx and Edward Lewis estimated that McDonald's could lose up to 28 million customer visits annually, resulting in nearly $482 million in lost revenue, roughly 0.9% of the company's sales, according to the concern is that GLP-1 drugs may shift eating habits, especially among lower-income consumers, who are the fast food chain's target market and who might cut back on dining out and keep those new habits long-term, as per CBS analysts pointed out that the "Behaviour changes extend beyond the individual user — reshaping group dining, influencing household routines and softening habitual demand. A 1% drag today could easily build to 10% or more over time, particularly for brands skewed toward lower income consumers or group occasions," quoted CBS to the pressure, rising prices and inflation might make it even harder for McDonald's to maintain its appeal to its customers, as per the report. The analysts highlighted that, "Consumers are showing clear signs of pricing fatigue after years of aggressive menu inflation," adding, "Although the gap between eating out and at home has narrowed, it remains historically wide, reinforcing value concerns," quoted CBS the adoption of the GLP-1 drugs has yet to reach a wider audience, as only 12% of Americans have tried the drugs, and currently just 6% of the adult population uses them, as per the the managing director and restaurant and food distributors analyst at BTIG global financial services, Peter Saleh said, "I don't think there would be a meaningful GLP-1 impact on McDonald's right now, but that's not to say that in three or four years that won't be the case," adding, "I just don't think we are there yet," quoted CBS medications that help regulate blood sugar and suppress appetite, often used for weight loss, as per to $482 million a year, according to some analysts.
